About the Company
eloxx pharmaceuticals, inc. is a clinical-stage biopharmaceutical company developing novel rna-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. premature stop codons are point mutations that disrupt protein synthesis from messenger rna. as a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. these premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. read-through therapeutic development is focused on extending mrna half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. eloxx’s lead product candidate, elx-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. elx-02 is in the early stages of clin
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
26
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ELOX News
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Almirall obtains exclusive global rights to develop and commercialize ZKN-013 for the treatment of rare dermatological and ...
Eloxx Pharmaceuticals Inc ELOX
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) (“Eloxx” or the “Company”), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the U.S. Food and Drug ...
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new ...
PCSA Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are ...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating Agents ...
Eloxx Pharmaceuticals, Inc. (ELOX)
While getting kicked off an exchange typically signals about the biggest warning sign you can possibly receive, a (somewhat) rational argument exists for delisted stocks to buy. Psychologically ...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
Eloxx Pharmaceuticals, Inc. is engaged in the science of ribosome modulation, leveraging its innovative TURBO-ZM™ chemistry technology platform in an effort to develop novel Ribosome Modulating ...
Eloxx Pharmaceuticals, Inc. Common Stock (ELOX)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green highlights the top performing ETF by % change in the past ...
Eloxx Pharmaceuticals, Inc. (ELOX)
*Close price adjusted for splits.**Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermatological diseases
March 13, 2024 (GLOBE NEWSWIRE) -- Almirall, S.A. (BME:ALM) and Eloxx Pharmaceuticals, Inc. (OTC: ELOX) announced today that the companies have entered into an exclusive license agreement for the ...
Eloxx Pharmaceuticals Inc (ELOX)
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead ...
Loading the latest forecasts...